問卷

TPIDB > Search Result

Search Result

篩選

List

5307Cases

2025-01-01 - 2029-12-31

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2025-01-01 - 2031-01-26

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2025-01-01 - 2031-01-26

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2025-01-01 - 2031-01-26

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2025-01-01 - 2028-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2025-01-01 - 2026-12-31

Others

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
1Sites

Recruiting1Sites

2025-01-01 - 2029-12-12

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites

2025-01-07 - 2027-12-31

Others

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
1Sites

Recruiting1Sites

2025-01-10 - 2031-05-31

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2026-06-01 - 2030-12-31

Phase III

Not yet recruiting
Multicenter, Phase III, Randomized, Placebo-controlled, Double-blind Study of Combination Therapy with D07001 Softgel Capsules and Capecitabine Versus Placebo and Capecitabine in Participants with Advanced Biliary Tract Cancer after Treatment Failure with Gemcitabine, Platinum, and FOLFOX or Irinotecan Regimens
  • Condition/Disease

    Biliary Tract Cancer (BTC)

  • Test Drug

    CAPECITABINE D07001-Softgel Capsules Placebo 艾結達膜衣錠 500 毫克 克癌特膜衣錠150毫克 克癌特膜衣錠500毫克 截瘤達錠500毫克

Participate Sites
9Sites

Not yet recruiting9Sites